Escient Pharmaceuticals IPO

Escient Pharmaceuticals is a biotech company specializing in the treatment of neurosensory-inflammatory disorders. Escient’s therapeutic programs apply state-of-the-art chemistries and biological understanding for its highly differentiated treatments using a novel class of cellular receptors called Mass-related G protein-coupled receptors (MRGPRS) that can detect and target a broad range of neuro-diseases.

Register for Details

For more details on financing and valuation for Escient Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Escient Pharmaceuticals's ticker symbol?

Escient Pharmaceuticals does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

What is Escient Pharmaceuticals's stock price?

The stock price for Escient Pharmaceuticals will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Who are Escient Pharmaceuticals's major investors?

Cowen Group
Perceptive Advisors
Redmile Group
Sanofi Genzyme BioVentures
Osage Partners
The Column Group
Altitude Life Science Ventures
NEA

Escient Pharmaceuticals Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
11/28/2022 Series C $120MM raised $XXX.XX $XXX.XX
9/14/2020 Series B $82.96MM raised $XXX.XX $XXX.XX
5/9/2018 Series A $40.55MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Escient Pharmaceuticals

Forge green plus iconForge green minus icon

What is Escient Pharmaceuticals funding to date?

Escient Pharmaceuticals has raised $243.51MM to date.
Forge green plus iconForge green minus icon

When was Escient Pharmaceuticals founded?

Escient Pharmaceuticals was founded in 2015.
Forge green plus iconForge green minus icon

Can you invest in Escient Pharmaceuticals?

Escient Pharmaceuticals is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Escient Pharmaceuticals share pre-IPO?

If you own Escient Pharmaceuticals pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Escient Pharmaceuticals a publicly traded company?

Escient Pharmaceuticals is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Other companies like Escient Pharmaceuticals in the Healthcare sector

Sector
Last Round Est. Valuation
$3.45B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$705.25MM
Sector
Last Round Est. Valuation
$656.14MM
Sector
Last Round Est. Valuation
$2B
Updated on: Nov 30, 2022

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.